HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

TRIM22 negatively regulates MHC-II expression

This item is licensed under:Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International

Files in This Item:
T22AI-BBA1_HUSCAP.pdf6.46 MBPDFView/Open
Please use this identifier to cite or link to this item:

Title: TRIM22 negatively regulates MHC-II expression
Authors: Inoue, Ayano Browse this author
Watanabe, Masashi Browse this author →KAKEN DB
Kondo, Takeshi Browse this author
Hirano, Satoshi Browse this author →KAKEN DB
Hatakeyama, Shigetsugu Browse this author →KAKEN DB
Keywords: TRIM22
Checkpoint blockade immunotherapy
Issue Date: Oct-2022
Publisher: Elsevier
Journal Title: Biochimica et Biophysica Acta (BBA) Molecular Cell Research
Volume: 1869
Issue: 10
Start Page: 119318
Publisher DOI: 10.1016/j.bbamcr.2022.119318
Abstract: The development of cancer treatment has recently achieved a remarkable breakthrough, and checkpoint blockade immunotherapy has received much attention. To enhance the therapeutic efficacy of checkpoint blockade immunotherapy, recent studies have revealed the importance of activation of CD4+ T cells via an in-crease in major histocompatibility complex (MHC) class II molecules in cancer cells. Here, we demonstrate that tripartite motif-containing (TRIM) 22, negatively regulates MHC-II expression. Gene knockout of TRIM22 using Cas9-sgRNAs led to an increase of MHC-II proteins, while TRIM22 overexpression remarkably decreased MHC-II proteins. mRNA levels of MHC-II and class II transactivator (CIITA), which plays an essential role in the regu-lation of MHC-II transcription, were not affected by TRIM22. Furthermore, TRIM22 knockout did not suppress the degradation of MHC-II protein but rather promoted it. These results suggest that TRIM22 decreases MHC-II protein levels through a combination of multiple mechanisms other than transcription or degradation. We showed that inhibition of TRIM22 can increase the amount of MHC-II expression in cancer cells, suggesting a possibility of providing the biological basis for a possible therapeutic target to potentiate checkpoint blockade immunotherapy.
Rights: © 2022. This manuscript version is made available under the CC-BY-NC-ND 4.0 license
Type: article (author version)
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 畠山 鎮次

Export metadata:

OAI-PMH ( junii2 , jpcoar_1.0 )

MathJax is now OFF:


 - Hokkaido University